2-May-2024
Kazia reports successful stage 1 completion of the EVT801 Phase 1 clinical trial in advanced cancer patients
11-Feb-2024
Professor takes big step in fighting cancer which claimed his daughter
23-Dec-2023
Parents of kids with DIPG say funding for trial urgently needed
23-Nov-2023
Kazia provides overview of Paxalisib related presentations from the Society of Neuro-Oncology 2023 Annual Meeting
1-May-2023
Kazia Therapeutics appoints Dr John Friend as new CEO
4-Apr-2023
Kazia Therapeutics to present new pipeline molecule data at AACR 2023
6-Mar-2023
Kazia Therapeutics forms clinical collaboration for Australian Phase 2 study of paxalisib, targeting childhood cancers
28-Feb-2023
Kazia Therapeutics raises A$7 million to fund R&D pipeline
6-Feb-2023
After a successful $4.5 million cap raise and with cancer trial results to come, Kazia is optimistic for 2023
31-Jan-2023
ASX rose 6.2% in January: Aus shares closed the day 0.07% lower
31-Jan-2023
High cost of living causes a fall in retail sales: ASX up 0.22% at noon
17-Jan-2023
Kazia Therapeutics CEO talks $4.5 million capital raise
16-Jan-2023
Kazia Therapeutics raising $4.5 million in placement; launches SPP
20-Dec-2022
Kazia Therapeutics exploring use of lead asset in other cancers: Edison Investment Research
14-Dec-2022
Kazia Therapeutics files patent as it continues to work with QIMT on cancer research
9-Dec-2022
SMH: ‘Waiting for your child to die is not an option’
8-Dec-2022
Kazia Therapeutics’ upcoming top-line data for EVT801 expected to be a share price catalyst: Edison Investment Research
5-Dec-2022
Kazia Therapeutics talks positive pre-clinical data for EVT801
1-Dec-2022
Almost all sectors higher: Aus shares close up 1%
1-Dec-2022
ASX opens to 7-month high after Powells positive news: Aus shares up 0.8%
30-Nov-2022
Kazia Therapeutics welcomes publication of positive pre-clinical data for EVT801 in peer-reviewed cancer research journal
1-Nov-2022
ASX increases slightly ahead of today's interest rate rise: Aus shares 0.3% higher at noon
28-Oct-2022
US tech earnings weighing down Aus tech sector: ASX falls 0.62% at noon
28-Oct-2022
Stocks of the Hour: Kazia Therapeutics, Green Technology Metals, Winsome Resources
28-Oct-2022
Kazia Therapeutics’ (ASX:KZA) paxalisib shows positive signals against preclinical melanoma models
5-Oct-2022
Kazia Therapeutics takes Phase 2 study of paxalisib international; opens two sites in Australia
27-Sep-2022
Stockhead Health and Biotech Investment Guide
8-Aug-2022
Stocks of the Hour: Kazia Therapeutics, Mesoblast, BHP &Oz Minerals
8-Aug-2022
ASX edges lower in morning trading, reporting season kicks off: Aus shares down 0.2% at noon
8-Aug-2022
Kazia Therapeutics gives progress report on GBM AGILE pivotal study for glioblastoma
7-Aug-2022
Kazia Therapeutics' promising data on treatment targeting brain metastases to be presented at conference
11-Jul-2022
Kazia Therapeutics forms new Scientific Advisory Board with world-leading experts in brain cancer
7-Jul-2022
Tech snaps 4-day winning streak, Iron ore miners rebound: ASX closes 0.8% higher
7-Jul-2022
Australia trade surplus hits record high, Chalice Mining soars on discovery: ASX up 0.2% at noon
7-Jul-2022
Stocks of the Hour: Elsight, Kazia Therapeutics, Chalice Mining
6-Jul-2022
Kazia Therapeutics gains US FDA Rare Paediatric Disease Designation for paxalisib in rare form of childhood brain cancer
30-Jun-2022
Kazia Therapeutics continues to make good progress on cancer treatment assets
17-Jun-2022
Kazia Therapeutics secures orphan drug designation for treatment of AT/RT tumours with paxalisib
14-Jun-2022
Stocks of the Hour: Kazia Therapeutics, Westgold Resources &Lake Resources
13-Jun-2022
Kazia Therapeutics welcomes presentation of positive paxalisib data at international symposium
8-Jun-2022
Kazia onto next chapter in Phase 2 brain metastases trial
7-Jun-2022
Kazia Therapeutics’ Phase 2 paxalisib study moves to expansion stage in breast cancer brain metastases cohort
31-May-2022
Kazia Therapeutics’ paxalisib now the subject of multi-drug platform study at the University Hospital, Zurich
11-May-2022
Sector Watch: Healthcare - M&Afever on the cards?
11-May-2022
Nasdaq jumps as Dow falls, Immutep, Antisense, Pushpay, AGL, Star on watch: ASX poised to open lower
5-May-2022
Kazia Therapeutics and its flagship asset have made significant progress against brain cancers: Pitt Street Research
2-May-2022
Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting
25-Apr-2022
Kazia Therapeutics establishes ‘at the market’ equity program
21-Apr-2022
Kazia Therapeutics completes Phase 2 study of glioblastoma drug Paxalisib; data to follow at conference
8-Apr-2022
Kazia Therapeutics encouraged by “promising data” on its cancer pipeline presented at AACR meeting in New Orleans
28-Feb-2022
Kazia Therapeutics initiates Phase II study of paxalisib for newly diagnosed and recurrent glioblastoma
24-Feb-2022
Kazia Therapeutics delivers on plans with two promising assets in human trials
12-Dec-2021
Kazia Therapeutics appoints US-based CFO to assist global market expansion
9-Dec-2021
Kazia Therapeutics' clinical paxalisib data maintains Speculative Buy rating from Bell Potter
3-Dec-2021
Kazia Therapeutics (ASX:KZA) announces positive results for brain cancer drug
3-Dec-2021
ASX up, Berkshire billionaire gives his views on crypto and will BHP benefit from rising iron ore prices?
2-Dec-2021
Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares up
29-Nov-2021
Kazia Therapeutics expands further in North America with Toronto glioblastoma study
15-Nov-2021
Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO
10-Nov-2021
Kazia Therapeutics welcomes start of PNOC study in childhood brain cancer, first patient enrolled
7-Nov-2021
Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial
4-Nov-2021
Kazia Therapeutics enrols first patient to phase I clinical trial of EVT801 cancer therapy
28-Oct-2021
Kazia Therapeutics gets boost with ‘buy’ call from Maxim Group and valuation upgrade from Edison
14-Oct-2021
Kazia Therapeutics’ paxalisib program data garners increased target share price of A$2.83 from Edison
14-Sep-2021
Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference
2-Sep-2021
Kazia Therapeutics receives full regulatory approval for EVT801 phase 1 study
9-Dec-2020
Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial
27-Apr-2020
Kazia Therapeutics (ASX:KZA) glioblastoma Phase II trial results